Roman Fabbricatore

Telisotuzumab adizutecan shows promising antitumor activity in advanced pancreatic cancer, with manageable safety and significant clinical benefits in a phase 1 study.

Regorafenib and nivolumab show promising results in advanced gastric cancer, offering improved response rates and quality of life compared to chemotherapy.

A recent study reveals promising outcomes for lung cancer patients who undergo rechallenge with different RET inhibitors after initial treatment failure.

Adding CAN-2409 to standard radiation therapy significantly improved disease-free survival and pathological complete response rates in intermediate-to-high-risk prostate cancer.

Atezolizumab plus cabozantinib or cabozantinib alone showed efficacy and manageable safety in second-line renal cell carcinoma.

Extended follow-up of MonumenTAL-1 shows talquetamab-tgvs yields durable ORRs and promising survival outcomes in relapsed/refractory multiple myeloma, with a tolerable safety profile.

An updated 4-year analysis indicates nivolumab/relatlimab offers comparable PFS and OS to nivolumab/ipilimumab in advanced melanoma, with lower toxicity.

Lenvatinib plus belzutifan showed durable activity and a consistent safety profile in advanced clear cell renal cell carcinoma after prior treatment.

External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for intermediate-risk prostate cancer.

Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.

A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage II/III rectal cancer.

Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.

NALRIFOX showed numerically better overall survival vs FOLFIRINOX as frontline treatment in PDAC, per real-world analysis results.

Baseline geriatric assessment vulnerabilities and quality of life scores correlate with overall survival in patients with metastatic pancreatic ductal adenocarcinoma receiving chemotherapy.

Evorpacept plus trastuzumab, paclitaxel, and ramucirumab showed improved survival and response rates over TRP alone in HER2-positive gastric/GEJ cancer.

An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with “good risk” DCIS treated without radiation therapy.

Venetoclax with hypomethylating agents produced better responses than HMAs alone in adult patients with myelodysplastic syndrome.

The combination of lenvatinib and pembrolizumab showed promising results in treating recurrent endometrial carcinoma, demonstrating significant antitumor activity and improved survival rates compared to standard therapy.